Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients
Curr Oncol. 2024 Apr 17;31(4):2274-2277. doi: 10.3390/curroncol31040168.ABSTRACTMaintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with Leishmania amastigotes. A Polymerase Chest Reaction testing confirmed the diagnosis of visceral leishmaniasis. Treatment with liposomal amphoteric...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Sophie Laroumagne Julie Tronchetti Herv é Dutau Philippe Astoul Source Type: research
Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data
This study used Pentavere's previously validated artificial intelligence (AI) to extract real-world data on the treatment patterns and outcomes of patients receiving CDK4/6i+endocrine therapy (ET) for HR+/HER2- ABC/MBC at Sinai Health in Toronto, Canada. Between 1 January 2016 and 1 July 2021, 48 patients were diagnosed with HR+/HER2- ABC/MBC and received CDK4/6i + ET. A total of 38 out of 48 patients received CDK4/6i + ET in 1L, of which 34 of the 38 (89.5%) received palbociclib + ET. In 2L, 12 of the 21 (57.1%) patients received CDK4/6i + ET, of which 58.3% received abemaciclib. In 3L, most patients received chemotherapy...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Ruth Moulson Guillaume Feug ère Tracy S Moreira-Lucas Florence Dequen Jessica Weiss Janet Smith Christine Brezden-Masley Source Type: research
The Evaluation and Management of Lung Metastases in Patients with Giant Cell Tumors of Bone in the Denosumab Era
In this study, we conducted a meta-analysis of the contemporary literature to evaluate all management strategies for GCTB metastases. A combination of the terms "lung metastases", "giant cell tumor", "bone", "treatment", and "oncologic outcomes" returned 133 patients meeting our inclusion criteria: 64 males and 69 females, with a median age of 28 years (7-63), at the onset of primary GCTB. Lung metastases typically occur at a mean interval of 26 months (range: 0-143 months) after treatment of the primary site, commonly presenting as multiple and bilateral lesions. Various treatment approaches, including surgery, chemothera...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Giulia Trovarelli Arianna Rizzo Mariachiara Cerchiaro Elisa Pala Andrea Angelini Pietro Ruggieri Source Type: research
Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia
Curr Oncol. 2024 Apr 9;31(4):2145-2157. doi: 10.3390/curroncol31040159.ABSTRACTNon-small-cell lung cancer (NSCLC) has experienced several diagnostic and therapeutic changes over the past two decades. However, there are few studies conducted with real-world data regarding the evolution of the cost of these new drugs and the corresponding changes in the survival of these patients. We collected data on patients diagnosed with NSCLC from the tumor registry of the University Hospital of Vic from 2002 to 2021. We analyzed the epidemiological and pathological characteristics of these patients, the diverse oncological treatments a...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Marta Parera Roig David Compte Colom é Gemma Basaga ña Colomer Emilia Gabriela Sardo Mauricio Alejandro Tournour Silvia Gri ñó Fernández Arturo Ivan Ominetti Emma Puigoriol Juvanteny Jos é Luis Molinero Polo Daniel Badia Jobal Nadia Espejo-Herrera Source Type: research
True Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations-Brief Report
Curr Oncol. 2024 Apr 5;31(4):2067-2075. doi: 10.3390/curroncol31040153.ABSTRACTDonor cell leukemia (DCL) is a rare complication after allogeneic hematopoietic stem cell transplantation (HSCT) accounting for 0.1% of relapses and presenting as secondary leukemia of donor origin. Distinct in phenotype and cytogenetics from the original leukemia, DCL's clinical challenge lies in its late onset. Its origin is affected by donor cell anomalies, transplant environment, and additional mutations. A 43-year-old woman, treated for early stage triple-negative breast cancer, developed mixed-phenotype acute leukemia (MPAL), 12 years late...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Mich èle Hoffmann Yara Banz J örg Halter Jacqueline Schoumans Jo ëlle Tchinda Ulrike Bacher Thomas Pabst Source Type: research
The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review
Curr Oncol. 2024 Apr 3;31(4):1994-2023. doi: 10.3390/curroncol31040149.ABSTRACTMelatonin is a multifunctional hormone regulator that maintains homeostasis through circadian rhythms, and desynchronization of these rhythms can lead to gastrointestinal disorders and increase the risk of cancer. Preliminary clinical studies have shown that exogenous melatonin alleviates the harmful effects of anticancer therapy and improves quality of life, but the results are still inconclusive due to the heterogeneity of the studies. A personalized approach to testing clinical parameters and response to integrative treatment with nontoxic an...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Eugeniy Smorodin Valentin Chuzmarov Toomas Veidebaum Source Type: research
High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment
CONCLUSIONS: There have not been long-term follow-ups of patients' oncologic and obstetric outcomes. As patients should be comprehensively informed, more detailed case reports or series with longer follow-up periods are needed.PMID:38668047 | PMC:PMC11048790 | DOI:10.3390/curroncol31040144 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Gregor Vivod Sebastjan Merlo Nina Kovacevic Source Type: research
Demographic Analysis of Cancer Research Priorities and Treatment Correlations
In conclusion, this study provides valuable insights into the complexity of cancer research priorities and treatment correlations in a European context. It emphasizes the importance of a multifaceted, patient-centred approach to cancer research and treatment, highlighting the need for ongoing support, adaptation, and collaboration to address the ever-changing landscape of oncology.PMID:38668042 | PMC:PMC11048756 | DOI:10.3390/curroncol31040139 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Denis Horgan Marc Van den Bulcke Umberto Malapelle Nicola Normanno Ettore D Capoluongo Arsela Prelaj Carmelo Rizzari Aliki Stathopoulou Jaya Singh Marta Kozaric France Dube Manuel Ottaviano Stefania Boccia Gabriella Pravettoni Ivana Cattaneo N úria Malat Source Type: research
Chemotherapy-induced nausea and vomiting in pediatric oncology patients: 2023 recommendations from the Supportive Care Committee of the French Society of Cancer in Children and Adolescents
Bull Cancer. 2024 Apr 25:S0007-4551(24)00123-1. doi: 10.1016/j.bulcan.2024.02.017. Online ahead of print.ABSTRACTChemotherapy-induced nausea and vomiting (CINV) are frequent and dreaded side effects in cancer treatments. CINV has a major impact on patient's condition and quality of life. Prophylaxis is tailored to patient's profile and the emetogenic level of their chemotherapy. The aim of this study is to update the recommendations for CINV prevention and management in pediatric onco-hematology for use in France, by adapting the guidelines of the Pediatric Oncology Group of Ontario (POGO). Clinical practice guideline adap...
Source: Bulletin du Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Marie Charlotte Renaux Torres S éverine Bouttefroy Ma ïna Letort-Bertrand V éronique Maurel Samia Mouffak Florian Scott é Florian Slimano Pauline Treguier L Lee Dupuis Marilyne Poir ée Sandrine Thouvenin-Doulet Source Type: research
The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation
CONCLUSION: Normalizing both biomarkers emerged as the most effective predictive marker for the 1-year recurrence rate, regardless of BRCA mutational status. A negative HE4 value can be a useful predictor for 1-year recurrence-free survival in patients with BRCA mutations.PMID:38670560 | DOI:10.3802/jgo.2024.35.e80 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 26, 2024 Category: OBGYN Authors: Young Joo Lee Woojin Kim Soomin Hong Yong Jae Lee Jung-Yun Lee Sang Wun Kim Sunghoon Kim Young Tae Kim Eun Ji Nam Source Type: research
Geographic variation in breast reconstruction surgery after mastectomy for females with breast cancer in Alberta, Canada
CONCLUSION: We found an overall postmastectomy rate of breast reconstruction of 11.9%, and we identified geographic variation. Predictors of reconstruction in Alberta were similar to those previously described in the literature, specifically with patients in rural communities having lower rates of reconstruction than their urban counterparts. These results suggest that further interventions are required to identify the specific barriers to reconstruction within rural communities and to create strategies to ensure equitable access to all residents.PMID:38670581 | PMC:PMC11052580 | DOI:10.1503/cjs.003823 (Source: Canadian Journal of Surgery)
Source: Canadian Journal of Surgery - April 26, 2024 Category: Surgery Authors: Yifu Huang Jenna-Lynn B Senger Lisa Korus Rhonda J Rosychuk Source Type: research
Considerations for medical nutrition therapy management of the critically ill patient with hematological malignancies: A narrative review
Nutr Clin Pract. 2024 Apr 26. doi: 10.1002/ncp.11152. Online ahead of print.ABSTRACTPatients with hematological malignancies (HMs) are more frequently admitted now than in the past to the intensive care unit (ICU) due to more aggressive approaches in primary therapy of HMs and the need for critical care support. Pathophysiological alterations derived from HMs and the different hematological therapies, such as chemotherapy, negatively affect gastrointestinal (GI) function, metabolism, and nutrition status. Further, malnutrition strongly influences outcomes and tolerance of the different hematological therapies. In consequen...
Source: Nutrition in Clinical Practice - April 26, 2024 Category: Nutrition Authors: Juan Carlos Lopez-Delgado Jayshil J Patel Christian Stoppe Stephen A McClave Source Type: research
Emerging From the Haze ™: Pilot Feasibility Study Comparing Two Virtual Formats of a Cognitive Rehabilitation Intervention
Oncol Nurs Forum. 2024 Apr 18;51(3):223-242. doi: 10.1188/24.ONF.223-242.ABSTRACTOBJECTIVES: To gather feasibility and preliminary data comparing two virtual delivery methods for providing Emerging From the Haze™ (Haze) to cancer survivors compared to waitlist control (WLC).SAMPLE & SETTING: Eligible participants (N = 93) reported cancer-related cognitive impairment following chemotherapy for stage I-III solid tumors, Hodgkin lymphoma, or non-Hodgkin lymphoma.METHODS & VARIABLES: A three-arm randomized design was used to compare virtual live group presentation of Haze sessions, virtual prerecorded Haze group sess...
Source: Oncology Nursing Forum - April 26, 2024 Category: Nursing Authors: Jamie S Myers Jeffrey C Wertheimer Jaromme Geebum Kim Jianghua He Celina H Shirazipour Dedrick Hooper Mary Penne Mays Jennifer R Klemp Carli Zegers Arash Asher Source Type: research
Stress and Coping in Patients With Cancer With Depression and Sleep Disturbance
Oncol Nurs Forum. 2024 Apr 18;51(3):243-262. doi: 10.1188/24.ONF.243-262.ABSTRACTOBJECTIVES: To evaluate for differences in global, cancer-specific, and cumulative life stress, as well as resilience and use of various coping strategies among five groups (no depression or sleep disturbance, no depression and moderate sleep disturbance, subsyndromal depression and very high sleep disturbance, moderate depression and moderate sleep disturbance [Both Moderate]; and high depression and very high sleep disturbance [Both High]).SAMPLE & SETTING: Patients (N = 1,331) receiving chemotherapy were recruited from outpatient oncolo...
Source: Oncology Nursing Forum - April 26, 2024 Category: Nursing Authors: Alejandra Calvo-Schimmel Joosun Shin Carolyn S Harris Lisa Morse Steven M Paul Bruce A Cooper Yvette P Conley Fay Wright Marilyn J Hammer Jon D Levine Christine Miaskowski Source Type: research
Chemotherapy-induced nausea and vomiting in pediatric oncology patients: 2023 recommendations from the Supportive Care Committee of the French Society of Cancer in Children and Adolescents
Bull Cancer. 2024 Apr 25:S0007-4551(24)00123-1. doi: 10.1016/j.bulcan.2024.02.017. Online ahead of print.ABSTRACTChemotherapy-induced nausea and vomiting (CINV) are frequent and dreaded side effects in cancer treatments. CINV has a major impact on patient's condition and quality of life. Prophylaxis is tailored to patient's profile and the emetogenic level of their chemotherapy. The aim of this study is to update the recommendations for CINV prevention and management in pediatric onco-hematology for use in France, by adapting the guidelines of the Pediatric Oncology Group of Ontario (POGO). Clinical practice guideline adap...
Source: Bulletin du Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Marie Charlotte Renaux Torres S éverine Bouttefroy Ma ïna Letort-Bertrand V éronique Maurel Samia Mouffak Florian Scott é Florian Slimano Pauline Treguier L Lee Dupuis Marilyne Poir ée Sandrine Thouvenin-Doulet Source Type: research
